1Gines P,Jimenez W. Aquaretic agents: a new potential treatmentof dilutional hyponatremia in cirrhosis. J Hepatol, 1996, 24:506-512.
2Gin, s P, Guevara M. Hyponatremia in cirrhosis: pathogenesis,clinical significance and management. Hepatology?2008, 48 : 1002-1010.
3Heuman DM, Abou—Assi SG, Habib A, et al. Persistent: ascitesand low sernm sodium identify patients with cirrhosis and lowMELD scoyes who are at high risk for early death. Hepatology,2004,40:802-810.
4Zwingmann C, Leibfritz D. Ammonia toxicity under hyponatremicconditions in astrocytes: de novo synthesis of amino acids for theosmoregulatory response. Neurochem Int, 2005, 47: 39-50.
5Bacearo ME, Guevara M, Tone A, et al. Hyponatremiapredisposesto hepatic eneephalopathy in patients withcirrhosis. Results of aprospective study with time, dependent analysis. Hepatology,2006,44:233A.
7Londono MC, Cardenas A, Guevara M, et al. MELDscore and se-rum sodium in the prediction of survival of patients with cirrhosis a-waiting liver transplantation, Gut, 2007,56: 1283-1290.
8Ruf AE, Kremers WK,Chavez LL, et al. Addition of serum sodi-uminto the MELD score predicts waiting list mortalitybetter thanMELD alone. Liver Transpl, 2005,11 :336-343.
9Cardenas A,Gines P. Dilutional hyponatremia, hepatorenal syn-drome and liver transplantation. Gastroenterol Hepatol, 2008,31:29-36.
10Yun BC,Kim WR, Benson JT, et al. Impact of pretransplant hy-ponatremia on outcomefollowing liver transplantation. Hepatology*2009, 49:1610-1615.
